Verbessem P.

Methods	52‐week double‐blind, in parallel study. Method of randomisation: unbalanced randomisation (Creatine:Placebo ‐ 2:1). Full random allocation was not possible. Results presented for each arm of the trial. Intention‐to‐treat data analysis. Location: 1 centre (Belgium).
Participants	42 patients, 3 drop‐outs. 15 male and 26 female patients completed the trial. Mean age of participants: 49,8±2,2 years. Mean duration of disease: 8,0±1,5 years. Inclusion criteria: HD (genetic diagnosis), functional stages I‐III, stable medication for at least 3 months. Exclusion criteria: history of renal pathology, existing albuminuria, prior creatine use.
Interventions	Oral Creatine 5 g/day (87 patients) and placebo, identical in appearance and taste (30 patients). No titration.
Outcomes	Primary: change in static and dynamic force. Secondary: Change in UHDRS items. Change in cardiorespiratory fitness. Change in bimanual coordination skill.
Notes	Negative for efficacy measures.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate

ADL ‐ Activities of daily living. 
 BZD ‐ Benzodiazepine. 
 CAG ‐ Glutamine. 
 CERAD ‐ Consortium to Establish a Registry for Alzheimer’s Disease. 
 CNS ‐ Central Nervous System. 
 EPA ‐ Eicosapentaenoic acid. 
 HD ‐Huntington's disease. 
 MMSE ‐ Mini‐Mental State Examination. 
 MRI ‐ Magnetic Ressonance Imaging. 
 mTFC ‐ modified Total Functioning Capacity. 
 PET ‐ Positron Emission Tomography. 
 QNE ‐ Quantified Neurological Examination. 
 TFC ‐ Total Functioning Capacity. 
 TMS ‐ Total Motor Score. 
 UHDRS ‐Unified Huntington Disease Revised Scale. 
 WAIS‐R ‐ Wechsler Adult Intelligence Scale‐revised.

WMS ‐ Wechsler Memory Scale.